嗜睡症市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、按診斷、按治療、按最終用戶、按地區和競爭細分，2020 年至 2030 年

2024 年全球發作性睡病市場價值為 34.3 億美元，預計到 2030 年將達到 52.4 億美元，預測期內的複合年成長率為 7.45%。全球發作性睡病市場正在穩步成長，這得益於人們對該疾病認知的不斷提高以及診斷技術和治療方案的進步。發作性睡病是一種慢性神經系統疾病，其特徵是白天過度嗜睡和突然肌肉無力（也稱為猝倒），近年來得到了更多的重視，導致全球診斷率更高。推動市場成長的主要因素之一是開發創新療法，以改善症狀管理和患者生活品質。例如，美國國家神經疾病和中風研究所估計美國有 135,000 至 200,000 人患有發作性睡病。壓力水平的上升導致盛行率上升，因此預計未來幾年確診的發作性睡病患者數量將會增加。同樣，根據美國神經病學會的研究，在歐洲國家，該疾病的盛行率為每十萬人20至67人不等。中樞神經系統興奮劑等傳統治療方法已被食慾素受體激動劑和緩釋製劑等新型藥物所補充，這些藥物的療效和便利性均有所提升。這些進展有助於滿足那些常常受現有療法限制困擾的患者尚未滿足的醫療需求。然而，市場仍面臨挑戰，包括因發作性睡病的症狀與其他睡眠障礙或神經系統疾病重疊而導致的漏診和誤診。診斷延遲可能會妨礙及時治療，並對患者的預後產生負面影響。

一些先進療法的高昂成本可能會限制資源匱乏地區患者的治療，從而限制整體市場覆蓋範圍。從地理來看，市場在醫療基礎設施完善且對睡眠障礙認知度較高的地區最為發達。同時，隨著醫療體系的完善和診斷能力的提升，新興市場預計將迎來更快的成長。研發投入的不斷增加也為新型治療方法鋪平了道路，包括旨在更好地監測和管理發作性睡病症狀的個人化醫療和數位健康解決方案。隨著科技進步不斷改善診斷和治療方案，全球發作性睡病市場前景光明，為改善全球患者預後和提高生活品質帶來了希望。

關鍵市場促進因素

睡眠障礙盛行率上升

主要市場挑戰

漏診及誤診

主要市場趨勢

創新療法的出現

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：臨床試驗分析

第6章：全球嗜睡症市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型（類型 1、類型 2、其他）
  • 按診斷（多導睡眠圖、多次睡眠潛伏期測試、其他）
  • 依治療方法（興奮劑、抗憂鬱劑、羥基丁酸鈉等）
  • 按最終用戶（醫院、診所、零售藥局、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第7章：北美嗜睡症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第8章：歐洲嗜睡症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第9章：亞太地區嗜睡症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第10章：南美洲嗜睡症市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 11 章：中東和非洲嗜睡症市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 12 章：市場動態

• 驅動程式
• 嗜睡症盛行率上升
• 政府機關的措施日益增多
• 挑戰
• 與嗜睡症藥物相關的不良反應。
• 與發作性睡病治療相關的誤診

第13章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 14 章：全球嗜睡症市場：SWOT 分析

第 15 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 16 章：競爭格局

• Jazz Pharmaceuticals Plc.
• BIOPROJET.
• Arena Pharmaceuticals, Inc.
• Graymark Healthcare, Inc.
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Novartis AG.
• Shire.
• Shionogi Inc.
• Ligand Pharmaceuticals, Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

Global Narcolepsy Market was valued at USD 3.43 billion in 2024 and is expected to reach USD 5.24 billion by 2030 with a CAGR of 7.45% during the forecast period. The global narcolepsy market is experiencing steady growth, driven by increasing awareness of the disorder and advancements in diagnostic techniques and treatment options. Narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness and sudden muscle weakness known as cataplexy, has gained more recognition in recent years, leading to higher diagnosis rates worldwide. One of the primary factors fueling market growth is the development of innovative therapies that improve symptom management and patient quality of life. For instance, the National Institute of Neurological Disorders and Stroke estimates 135,000 to 200,000 people in the U.S. have narcolepsy. Rising stress levels contribute to increasing prevalence, so the number of diagnosed narcolepsy patients is expected to grow in the coming years. Similarly, according to the study conducted by the American Academy of Neurology, the prevalence of the disease varies from 20 to 67 per 100,000 individuals in European countries. Traditional treatments such as central nervous system stimulants have been supplemented by newer medications, including orexin receptor agonists and extended-release formulations, which offer enhanced efficacy and convenience. These advancements have helped address the unmet medical needs of patients who often struggle with the limitations of existing therapies. However, the market still faces challenges, including the underdiagnosis and misdiagnosis of narcolepsy due to symptom overlap with other sleep disorders or neurological conditions. This delay in diagnosis can hinder timely treatment and negatively impact patient outcomes.

The high cost of some advanced therapies may restrict access for patients in low-resource settings, limiting the overall market reach. Geographically, the market is most developed in regions with well-established healthcare infrastructure and greater awareness of sleep disorders. Meanwhile, emerging markets are expected to witness faster growth as healthcare systems improve and diagnostic capabilities expand. Increasing investment in research and development is also paving the way for novel therapeutic approaches, including personalized medicine and digital health solutions aimed at better monitoring and managing narcolepsy symptoms. The global narcolepsy market holds promising potential as advancements continue to improve diagnosis and treatment options, offering hope for better patient outcomes and enhanced quality of life worldwide.

Key Market Drivers

Rising Prevalence of Sleep Disorders

The rising prevalence of sleep disorders is a significant factor influencing the growth of the global narcolepsy market. Sleep disorders encompass a wide range of conditions that disrupt normal sleep patterns, including insomnia, sleep apnea, restless leg syndrome, and narcolepsy. Among these, narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, sudden muscle weakness (cataplexy), and disrupted nighttime sleep. As awareness of sleep health improves and diagnostic techniques become more sophisticated, more individuals are being identified with these conditions, contributing to a growing patient population seeking medical intervention.Several lifestyle and environmental factors have contributed to the increasing occurrence of sleep disorders worldwide. Modern lifestyles marked by high stress levels, irregular sleep schedules, increased screen time, and urbanization have negatively impacted sleep quality for many people. Additionally, the global rise in comorbid conditions such as obesity, mental health disorders, and cardiovascular diseases-which are closely linked to sleep disturbances-has further fueled the prevalence of sleep-related issues. This broader trend creates a conducive environment for the narcolepsy market as individuals experiencing symptoms are more likely to seek specialized treatment.

From a market perspective, the rising prevalence translates into heightened demand for effective diagnostic tools and therapeutic solutions. Improved screening methods allow for earlier and more accurate diagnosis, enabling timely intervention. As more patients are diagnosed with narcolepsy, pharmaceutical companies and healthcare providers are motivated to develop and offer advanced treatment options tailored to patient needs. This includes innovative drugs that target underlying causes or provide better symptom control, as well as supportive therapies that enhance quality of life. The growing patient pool encourages investment in research and development, further advancing the narcolepsy treatment landscape. Healthcare systems worldwide are also recognizing the economic and social burdens of untreated sleep disorders, prompting initiatives to improve access to care. Overall, the rising prevalence of sleep disorders acts as a crucial driver for the narcolepsy market, fostering growth and innovation aimed at meeting increasing patient demand.

Key Market Challenges

Underdiagnosis and Misdiagnosis

Underdiagnosis and misdiagnosis remain significant challenges impacting the growth and effectiveness of the global narcolepsy market. Narcolepsy is a complex neurological disorder characterized by symptoms such as excessive daytime sleepiness, cataplexy (sudden muscle weakness), and disrupted nighttime sleep. However, these symptoms often overlap with those of other more common conditions, including insomnia, depression, epilepsy, and general fatigue. This similarity frequently leads to confusion among healthcare providers, resulting in delayed or incorrect diagnoses. The underdiagnosis of narcolepsy is widespread, with many patients remaining undiagnosed for years after symptom onset. This delay can have serious consequences on patient quality of life, as untreated symptoms impair daily functioning, cognitive performance, and emotional wellbeing. Moreover, underdiagnosis limits the number of patients receiving appropriate treatment, directly affecting the market size and growth potential for narcolepsy therapies.

Misdiagnosis also poses a critical problem, as patients may be treated for conditions they do not have, leading to ineffective therapy and further deterioration of their condition. The absence of specialized sleep disorder clinics and limited access to advanced diagnostic tools in many regions exacerbate this issue. Additionally, a lack of awareness and training among general practitioners and even some specialists contributes to diagnostic challenges. From a market perspective, overcoming underdiagnosis and misdiagnosis is essential for unlocking the full potential of narcolepsy treatment demand. Improving awareness campaigns, enhancing education for healthcare professionals, and expanding access to reliable diagnostic methods such as polysomnography and multiple sleep latency tests are critical steps. As diagnosis rates improve, more patients will seek treatment, driving innovation and growth in the narcolepsy therapeutics market.

Key Market Trends

Emergence of Innovative Therapies

The emergence of innovative therapies is transforming the global narcolepsy market by offering more effective and patient-friendly treatment options. Traditional narcolepsy treatments primarily focused on managing symptoms like excessive daytime sleepiness and cataplexy through stimulants and sodium oxybate. However, these treatments often had limitations related to side effects, dosing frequency, and variable efficacy, which impacted patient adherence and quality of life. Recent advancements in pharmacology have introduced novel therapies targeting the underlying mechanisms of narcolepsy, particularly the orexin (hypocretin) system, which plays a crucial role in regulating wakefulness. Orexin receptor agonists represent a new class of drugs designed to directly address the root cause of narcolepsy rather than just alleviating symptoms. These innovative agents have demonstrated promising results in clinical trials, showing improved efficacy with fewer side effects compared to conventional medications.

The pharmaceutical companies are developing extended-release formulations of existing drugs, such as once-nightly sodium oxybate, which improve convenience and encourage better adherence by reducing the need for multiple daily doses. This approach enhances patient compliance and overall treatment outcomes. The market is also witnessing the introduction of therapies approved for pediatric use, expanding treatment availability to younger patients who were previously underserved. This broadens the patient base and underscores the importance of inclusive treatment development. The rise of innovative therapies in the narcolepsy market is driving growth by meeting unmet clinical needs and improving patient quality of life. These advancements are encouraging ongoing research and investment, fostering a competitive landscape focused on delivering safer, more effective, and tailored treatment options for narcolepsy patients worldwide.

Key Market Players

• Jazz Pharmaceuticals Plc.
  • BIOPROJET.
  • Arena Pharmaceuticals, Inc.
  • Graymark Healthcare, Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
  • Novartis AG.
• Shire.
• Shionogi Inc.
• Ligand Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Narcolepsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Narcolepsy Market, By Type:

• Type 1
• Type 2
• Others

Narcolepsy Market, By Diagnosis:

• Polysomnogram
• Multiple Sleep Latency Test
• Others

Narcolepsy Market, By Treatment:

• Stimulants
• Antidepressants
• Sodium Oxybate
• Others

Narcolepsy Market, By End User:

• Hospitals
• Clinics
• Retail Pharmacies
• Others

Narcolepsy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Market.

Available Customizations:

Global Narcolepsy Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Narcolepsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Type 1, Type 2, Others)
  • 6.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 6.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 6.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map

7. North America Narcolepsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Type 1, Type 2, Others)
  • 7.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 7.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 7.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Narcolepsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By Treatment
      • 7.3.1.2.4. By End User
  • 7.3.2. Canada Narcolepsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By Treatment
      • 7.3.2.2.4. By End User
  • 7.3.3. Mexico Narcolepsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By Treatment
      • 7.3.3.2.4. By End User

8. Europe Narcolepsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Type 1, Type 2, Others)
  • 8.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 8.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 8.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Narcolepsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By Treatment
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Narcolepsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By Treatment
      • 8.3.2.2.4. By End User
  • 8.3.3. United Kingdom Narcolepsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By Treatment
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Narcolepsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By Treatment
      • 8.3.4.2.4. By End User
  • 8.3.5. Spain Narcolepsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By Treatment
      • 8.3.5.2.4. By End User

9. Asia-Pacific Narcolepsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Type 1, Type 2, Others)
  • 9.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 9.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 9.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Narcolepsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By Treatment
      • 9.3.1.2.4. By End User
  • 9.3.2. India Narcolepsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By Treatment
      • 9.3.2.2.4. By End User
  • 9.3.3. Japan Narcolepsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By Treatment
      • 9.3.3.2.4. By End User
  • 9.3.4. South Korea Narcolepsy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Diagnosis
      • 9.3.4.2.3. By Treatment
      • 9.3.4.2.4. By End User
  • 9.3.5. Australia Narcolepsy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Type
      • 9.3.5.2.2. By Diagnosis
      • 9.3.5.2.3. By Treatment
      • 9.3.5.2.4. By End User

10. South America Narcolepsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Type 1, Type 2, Others)
  • 10.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 10.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 10.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Narcolepsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By Treatment
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Narcolepsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By Treatment
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Narcolepsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By Treatment
      • 10.3.3.2.4. By End User

11. Middle East and Africa Narcolepsy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Type (Type 1, Type 2, Others)
  • 11.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 11.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 11.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Narcolepsy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Type
      • 11.3.1.2.2. By Diagnosis
      • 11.3.1.2.3. By Treatment
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Narcolepsy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Type
      • 11.3.2.2.2. By Diagnosis
      • 11.3.2.2.3. By Treatment
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Narcolepsy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Type
      • 11.3.3.2.2. By Diagnosis
      • 11.3.3.2.3. By Treatment
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.1.1 Increase in Prevalence of Narcolepsy
• 12.1.2 Growing Initiatives by Government Organizations
• 12.2. Challenges
• 12.2.1 Adverse effect related to narcolepsy drugs.
• 12.2.2 Misdiagnosis related to narcolepsy treatment

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Narcolepsy Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1 Jazz Pharmaceuticals Plc.
• 16.2 BIOPROJET.
• 16.3 Arena Pharmaceuticals, Inc.
• 16.4 Graymark Healthcare, Inc.
• 16.5 Mylan N.V.
• 16.6 Teva Pharmaceutical Industries Ltd.
• 16.7 Novartis AG.
• 16.8 Shire.
• 16.9 Shionogi Inc.
• 16.10 Ligand Pharmaceuticals, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer